The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.

Key Takeaways A new HIV shot taken twice a year was nearly 100% effective in trialsGlobal funding cuts could limit access to ...